← Back to Search

Part B - LT3001 and Aspirin for Stroke

Phase 1
Waitlist Available
Research Sponsored by Lumosa Therapeutics Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 days
Awards & highlights
Approved for 10 Other Conditions
All Individual Drugs Already Approved

Summary

This trial tests a new drug, LT3001, in healthy people to see if it's safe and how it behaves in the body. It also checks if LT3001 interacts with common medications like aspirin and blood thinners.

Eligible Conditions
  • Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of adverse events
Secondary study objectives
Changes from baseline in coagulation
Changes from baseline in platelet function test
Plasma PK parameters of Apixaban - AUC
+14 more

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B - LT3001 and DabigatranExperimental Treatment2 Interventions
Multiple doses of LT3001 and Dabigatran administered
Group II: Part B - LT3001 and ClopidogrelExperimental Treatment2 Interventions
Multiple doses of LT3001 and Clopidogrel administered
Group III: Part B - LT3001 and AspirinExperimental Treatment2 Interventions
Multiple doses of LT3001 and Aspirin administered
Group IV: Part B - LT3001 and ApixabanExperimental Treatment2 Interventions
Multiple doses of LT3001 and Apixaban administered
Group V: Part A - LT3001 Drug ProductExperimental Treatment1 Intervention
Multiple doses of LT3001 administered by intravenous infusion
Group VI: Part A - PlaceboPlacebo Group1 Intervention
Multiple doses of Placebo administered by intravenous infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Clopidogrel
FDA approved
Dabigatran
FDA approved
Acetylsalicylic acid
FDA approved
Apixaban
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Lumosa Therapeutics Co., Ltd.Lead Sponsor
7 Previous Clinical Trials
625 Total Patients Enrolled
3 Trials studying Stroke
290 Patients Enrolled for Stroke
Mimi Yeh, PhDStudy DirectorLumosa Phase 1 unit
~14 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top